Japan Looks At Drug Development To Deal With Rising Medical Expenses
This article was originally published in PharmAsia News
Japan faces the same realities involving rising national medical expenses as other developed nations; it is expected to pass the $505 billion mark this year and increase at the rate of $1.6 billion a year.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.